Richa Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richa Shah has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Kiran Acharya
New ERA, Rudramati Marga, Kalopul, Kathmandu, Nepal
15 shared publications - Mahfuzur Rahman
Graduate School of Public Health, St. Luke’s International University
15 shared publications - Manami Inoue
Division of Cohort Research, National Cancer Center Institute for Cancer Control
15 shared publications - Rei Haruyama
Bureau of Global Health Cooperation, Japan Institute for Health Security, Tokyo, Japan
15 shared publications - Sarah Krull Abe
Division of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan
15 shared publications - Shafiur Rahman
School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan
15 shared publications
Latest Publications
- 10 June 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103137
Cancer incidence and mortality among older adults in Asia: Estimates for 2022 and projections to 2050
- 10 June 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103137
Cancer incidence and mortality among older adults in Asia: Estimates for 2022 and projections to 2050
- 1 April 2026
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2026 (72) , 3-14
The direct costs of cancer care: a review of recent trends and variations in 39 countries
Background: The global rise in cancer incidence and survivorship is contributing to escalating health-care expenditure. Yet comprehensive and internationally comparable data on direct cancer costs worldwide remain scarce, limiting insights into cross-country spending patterns, their relationship to cancer outcomes, and future cost trajectories. Methods: We assembled data on direct cancer costs up to the year 2022 from academic journals, government statistical reports, and the grey literature. Drawing from 19 sources in 39 countries, we estimated total, per-patient, and per-capita cancer expenditure in US dollars (US$) by cancer type, assessing associations between spending and cancer outcomes, alongside recent trends. Results: Annual cancer costs varied substantially and reflected differences in national income, ranging from US$1989 per diagnosis (Ethiopia) to US$129 494 per diagnosis (United States). Annual costs per capita ranged from US$1.43 (Ethiopia) to US$713 (United States). Annual expenditure was positively correlated with survival for most cancers but showed diminishing returns in high-income countries. Moreover, expenditure had no apparent relation with overall cancer mortality. Where data were available, spending patterns by cancer type reflected country-specific incidence profiles. Across all countries, the 4 costliest cancers accounted for one-third to almost one-half (37%-48%) of direct cancer costs. In countries with reliable time series, costs rose steadily over time, with growth rates ranging from 1.4% (Japan, 2009-2022) to 9.3% (Republic of Korea, 2004-2022). These increases consistently outpaced gross domestic product growth by 1.0%-7.7% over the respective observation periods. Conclusion: Greater reforms to cancer control, and health-care more broadly, are required to ensure long-term fiscal sustainability while maximizing population health outcomes.
- 1 April 2026
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2026 (72) , 3-14
The direct costs of cancer care: a review of recent trends and variations in 39 countries
Background: The global rise in cancer incidence and survivorship is contributing to escalating health-care expenditure. Yet comprehensive and internationally comparable data on direct cancer costs worldwide remain scarce, limiting insights into cross-country spending patterns, their relationship to cancer outcomes, and future cost trajectories. Methods: We assembled data on direct cancer costs up to the year 2022 from academic journals, government statistical reports, and the grey literature. Drawing from 19 sources in 39 countries, we estimated total, per-patient, and per-capita cancer expenditure in US dollars (US$) by cancer type, assessing associations between spending and cancer outcomes, alongside recent trends. Results: Annual cancer costs varied substantially and reflected differences in national income, ranging from US$1989 per diagnosis (Ethiopia) to US$129 494 per diagnosis (United States). Annual costs per capita ranged from US$1.43 (Ethiopia) to US$713 (United States). Annual expenditure was positively correlated with survival for most cancers but showed diminishing returns in high-income countries. Moreover, expenditure had no apparent relation with overall cancer mortality. Where data were available, spending patterns by cancer type reflected country-specific incidence profiles. Across all countries, the 4 costliest cancers accounted for one-third to almost one-half (37%-48%) of direct cancer costs. In countries with reliable time series, costs rose steadily over time, with growth rates ranging from 1.4% (Japan, 2009-2022) to 9.3% (Republic of Korea, 2004-2022). These increases consistently outpaced gross domestic product growth by 1.0%-7.7% over the respective observation periods. Conclusion: Greater reforms to cancer control, and health-care more broadly, are required to ensure long-term fiscal sustainability while maximizing population health outcomes.
- Top Cited Papers
- 2 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 194-204
The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis
The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816
- 2 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 194-204
Top Cited PapersThe global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis
The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816
- 26 November 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 95, 102716
Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates
- 26 November 2024
- Published by Elsevier in Cancer Epidemiology
- Vol. 95, 102716
Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Background:Cervical cancer presents a considerable challenge in South Asia, notably in Nepal, where screening remains limited. Past research in Nepal lacked national representation and a thorough exploration of factors influencing cervical cancer screening, such as educational and socioeconomic disparities. This study aims to measure these gaps and identify associated factors in testing for early detection of cervical cancer among Nepalese women.Methods:Data from the 2019 Nepal Noncommunicable Disease Risk Factors survey (World Health Organization STEPwise approach to noncommunicable risk factor surveillance), involving 2,332 women aged 30 to 69 years, were used. Respondents were asked if they had undergone cervical cancer testing through visual inspection with acetic acid, Pap smear, or human papillomavirus test ever or in the past 5 years. The slope index of inequality (SII) and relative concentration index were used to measure socioeconomic and education-based disparities in cervical cancer test uptake.Results:Only 7.1% [95% confidence interval (CI): 5.1–9.9] Nepalese women had ever undergone cervical cancer testing, whereas 5.1% (95% CI: 3.4–7.5) tested within the last 5 years. The ever uptake of cervical cancer testing was 5.1 percentage points higher (SII: 5.1, 95% CI: −0.1 to 10.2) among women from the richest compared with the poorest households. Education-based disparities were particularly pronounced, with a 13.9 percentage point difference between highly educated urban residents and their uneducated counterparts (SII: 13.9, 95% CI: 5.8–21.9).Conclusions:Less than one in ten women in Nepal had a cervical cancer testing, primarily favoring higher educated and wealthier individuals.Impact:Targeted early detection and cervical cancer screening interventions are necessary to address these disparities and improve access and uptake.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Background:Cervical cancer presents a considerable challenge in South Asia, notably in Nepal, where screening remains limited. Past research in Nepal lacked national representation and a thorough exploration of factors influencing cervical cancer screening, such as educational and socioeconomic disparities. This study aims to measure these gaps and identify associated factors in testing for early detection of cervical cancer among Nepalese women.Methods:Data from the 2019 Nepal Noncommunicable Disease Risk Factors survey (World Health Organization STEPwise approach to noncommunicable risk factor surveillance), involving 2,332 women aged 30 to 69 years, were used. Respondents were asked if they had undergone cervical cancer testing through visual inspection with acetic acid, Pap smear, or human papillomavirus test ever or in the past 5 years. The slope index of inequality (SII) and relative concentration index were used to measure socioeconomic and education-based disparities in cervical cancer test uptake.Results:Only 7.1% [95% confidence interval (CI): 5.1–9.9] Nepalese women had ever undergone cervical cancer testing, whereas 5.1% (95% CI: 3.4–7.5) tested within the last 5 years. The ever uptake of cervical cancer testing was 5.1 percentage points higher (SII: 5.1, 95% CI: −0.1 to 10.2) among women from the richest compared with the poorest households. Education-based disparities were particularly pronounced, with a 13.9 percentage point difference between highly educated urban residents and their uneducated counterparts (SII: 13.9, 95% CI: 5.8–21.9).Conclusions:Less than one in ten women in Nepal had a cervical cancer testing, primarily favoring higher educated and wealthier individuals.Impact:Targeted early detection and cervical cancer screening interventions are necessary to address these disparities and improve access and uptake.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S5 shows the results of a logistic regression model identifying the risk factors associated with cervical cancer testing uptake within the last five years
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S5 shows the results of a logistic regression model identifying the risk factors associated with cervical cancer testing uptake within the last five years
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S5 shows the results of a logistic regression model identifying the risk factors associated with cervical cancer testing uptake within the last five years
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S5 shows the results of a logistic regression model identifying the risk factors associated with cervical cancer testing uptake within the last five years
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Background:Cervical cancer presents a considerable challenge in South Asia, notably in Nepal, where screening remains limited. Past research in Nepal lacked national representation and a thorough exploration of factors influencing cervical cancer screening, such as educational and socioeconomic disparities. This study aims to measure these gaps and identify associated factors in testing for early detection of cervical cancer among Nepalese women.Methods:Data from the 2019 Nepal Noncommunicable Disease Risk Factors survey (World Health Organization STEPwise approach to noncommunicable risk factor surveillance), involving 2,332 women aged 30 to 69 years, were used. Respondents were asked if they had undergone cervical cancer testing through visual inspection with acetic acid, Pap smear, or human papillomavirus test ever or in the past 5 years. The slope index of inequality (SII) and relative concentration index were used to measure socioeconomic and education-based disparities in cervical cancer test uptake.Results:Only 7.1% [95% confidence interval (CI): 5.1–9.9] Nepalese women had ever undergone cervical cancer testing, whereas 5.1% (95% CI: 3.4–7.5) tested within the last 5 years. The ever uptake of cervical cancer testing was 5.1 percentage points higher (SII: 5.1, 95% CI: −0.1 to 10.2) among women from the richest compared with the poorest households. Education-based disparities were particularly pronounced, with a 13.9 percentage point difference between highly educated urban residents and their uneducated counterparts (SII: 13.9, 95% CI: 5.8–21.9).Conclusions:Less than one in ten women in Nepal had a cervical cancer testing, primarily favoring higher educated and wealthier individuals.Impact:Targeted early detection and cervical cancer screening interventions are necessary to address these disparities and improve access and uptake.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Background:Cervical cancer presents a considerable challenge in South Asia, notably in Nepal, where screening remains limited. Past research in Nepal lacked national representation and a thorough exploration of factors influencing cervical cancer screening, such as educational and socioeconomic disparities. This study aims to measure these gaps and identify associated factors in testing for early detection of cervical cancer among Nepalese women.Methods:Data from the 2019 Nepal Noncommunicable Disease Risk Factors survey (World Health Organization STEPwise approach to noncommunicable risk factor surveillance), involving 2,332 women aged 30 to 69 years, were used. Respondents were asked if they had undergone cervical cancer testing through visual inspection with acetic acid, Pap smear, or human papillomavirus test ever or in the past 5 years. The slope index of inequality (SII) and relative concentration index were used to measure socioeconomic and education-based disparities in cervical cancer test uptake.Results:Only 7.1% [95% confidence interval (CI): 5.1–9.9] Nepalese women had ever undergone cervical cancer testing, whereas 5.1% (95% CI: 3.4–7.5) tested within the last 5 years. The ever uptake of cervical cancer testing was 5.1 percentage points higher (SII: 5.1, 95% CI: −0.1 to 10.2) among women from the richest compared with the poorest households. Education-based disparities were particularly pronounced, with a 13.9 percentage point difference between highly educated urban residents and their uneducated counterparts (SII: 13.9, 95% CI: 5.8–21.9).Conclusions:Less than one in ten women in Nepal had a cervical cancer testing, primarily favoring higher educated and wealthier individuals.Impact:Targeted early detection and cervical cancer screening interventions are necessary to address these disparities and improve access and uptake.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S3 shows the reasons for the uptake of cervical cancer test among Nepalese women by age groups.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S3 shows the reasons for the uptake of cervical cancer test among Nepalese women by age groups.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S4 shows the values of slope index of inequality (with 95% CI) for the cervical cancer test uptake among Nepalese women.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Supplementary Table S4 shows the values of slope index of inequality (with 95% CI) for the cervical cancer test uptake among Nepalese women.